Mangalam Drugs Defaults on Bank Loans Exceeding ₹15 Crore
Mangalam Drugs and Organics Limited has defaulted on loan obligations to Bank of Baroda and Bank of Maharashtra. Overdue amounts as of November 15, 2026, are ₹9.51 crore (Bank of Maharashtra) and ₹6.06 crore (Bank of Baroda). The company is arranging to clear the overdue amounts.
A default on bank loans can significantly impact the company's financial standing, credit rating, and operational capabilities, leading to potential legal actions or restructuring.
The company has disclosed a default on its bank loan obligations, which is a negative financial event.
Mangalam Drugs and Organics Limited has disclosed a default on its loan obligations to Bank of Baroda and Bank of Maharashtra, exceeding 30 days. The company reported that as of November 15, 2026, the overdue amount for Bank of Maharashtra's Cash Credit Account No. 60383561246 stands at ₹951.19 lakhs (approximately ₹9.51 crore). The default on this account began on October 17, 2025.
Furthermore, the company has defaulted on its loan obligations to Bank of Baroda for its Cash Credit Account No. 04170500000243. As of November 15, 2026, the overdue amount is ₹606.08 lakhs (approximately ₹6.06 crore), with the default starting on October 20, 2025.
The company stated that arrangements are being made to pay the overdue amounts as soon as possible. This disclosure is made in accordance with Regulation 30, Part A of Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, which mandates disclosure of defaults on payment of interest or principal.
What to do with a filing like this
Mangalam Drugs And Organics Limited filed this with the NSE as a statutory disclosure, categorised under fraud/defaults disclosure. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mangalam Drugs And Organics Limited. Read the original for the full detail.